SCYNEXIS logo
SCYNEXIS SCYX
$ 0.65 0.0%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

SCYNEXIS Financial Statements 2011-2025 | SCYX

Annual Financial Statements SCYNEXIS

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

70.3 M 78 M 129 M 79.4 M 50.6 M 31.6 M 49.2 M 57.2 M 55.6 M 61.1 M - - -

Shares

47.9 M 42.6 M 26.4 M 10.6 M 5.61 M 4.39 M 2.67 M 1.9 M 1.22 M 566 K - - -

Historical Prices

1.47 1.83 4.9 7.47 8.63 10.2 17.8 30.2 45.7 108 - - -

Net Income

67 M -62.8 M -32.9 M -55.2 M -53.7 M -12.5 M -25.1 M -30 M -32.6 M -4.23 M -30.5 M -11.5 M -

Revenue

140 M 5.09 M 13.2 M - 121 K 257 K 257 K 257 K 257 K 19 M 16.9 M 16.8 M -

Cost of Revenue

- - - - - - - - - 15.4 M 16.3 M - -

Gross Profit

- - - - - - - - - 3.58 M 552 K 2.47 M -

Operating Income

72.7 M -85.8 M -60.8 M -51.1 M -48.9 M -30 M -26.3 M -27.8 M -28.3 M -14.6 M -8.65 M - -

Interest Expense

3.13 M 5.2 M 2.66 M 1.18 M 986 K 1.63 M 1.46 M 351 K -11 K 48 K - - -

EBITDA

73.2 M -85.2 M -60.5 M -52.3 M -48.8 M -29.9 M -26.3 M -27.8 M -27.9 M -11 M -6.86 M -9.71 M -

Operating Expenses

67.5 M 90.8 M 74 M 50.8 M 49 M 30.2 M 26.6 M 28.1 M 28.6 M 15.9 M 8.74 M 13.7 M -

General and Administrative Expenses

20.9 M 63 M 49.9 M 14.6 M 10.6 M 8.68 M 8.25 M 8 M 12.2 M 7.57 M - - -

All numbers in USD currency

Quarterly Income Statement SCYNEXIS

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

49.9 M 49.7 M 49.4 M 38 M 48.6 M 48.5 M 48.2 M 37.2 M 47.9 M 47.8 M 47.8 M 32.7 M 47.5 M 43.3 M 32.1 M 28.7 M 26.6 M 26 M 25.8 M 19.7 M 10.6 M 10 M 9.74 M 9.74 M 5.57 M 5.33 M 49.3 M 48 M 47 M 46.8 M 33.6 M 29 M 27.1 M 25.8 M 25.4 M 24.6 M 23.4 M 14.6 M 13.9 M 13.9 M 13.9 M 12.2 M 8.52 M 8.51 M 8.5 M 5.18 M 334 K 334 K 336 K 336 K 336 K 336 K - - - - - - -

Net Income

-8.59 M -6.88 M -5.39 M - -2.81 M -14.5 M 411 K - -1.76 M 122 M -33.9 M - -29.6 M -13.3 M -5.45 M - -605 K 1.66 M -4.68 M - 909 K -6.38 M -7 M - -7.94 M -8.4 M -22.9 M - 351 K -10.8 M -4 M - -8.4 M -4.2 M -4.87 M -3.45 M -11.2 M -8.13 M -7.18 M -8.39 M -8.36 M -9.5 M -6.38 M - -3.8 M 2.23 M 412 K - -3.96 M -2.7 M -2.07 M - - - - - - - -

Revenue

334 K 1.36 M 257 K - 660 K 736 K 1.37 M - 1.76 M 131 M 1.13 M - 1.56 M 1.32 M 687 K - 516 K - 12 M - - - - - - 57 K 64 K - 64 K 64 K 64 K - 64 K 64 K 64 K 65 K 64 K 64 K 64 K 64 K 64 K 64 K 2.31 M - 2.56 M 2.82 M 2.88 M - 2.34 M 2.4 M 2.97 M - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3.23 M - 3.66 M 4.18 M 3.96 M - 3.99 M 4.4 M 4.15 M - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 66 K - 720 K 462 K 745 K - 177 K -171 K 647 K - - - - - - - -

Operating Income

-8.4 M -9.56 M -8.61 M - -10.3 M -9.24 M -9.51 M - -10.1 M 117 M -10.7 M - -21.8 M -21.7 M -19.7 M - -19.4 M -17.5 M -1.59 M - -11.5 M -11.8 M -12.5 M - -11.8 M -11.2 M -11.9 M - -6.3 M -7.66 M -7.23 M - -6.4 M -6.74 M -6.02 M -5.63 M -6.71 M -8.27 M -7.21 M -8.39 M -7.54 M -6.49 M -5.93 M - -4.54 M -4.01 M -2.46 M - -2.01 M -1.62 M -1.08 M - - - - - - - -

Interest Expense

- - - - - 197 K 205 K - 212 K 1.25 M 1.45 M - 1.38 M 1.23 M 1.06 M - 1.02 M 445 K 214 K - 330 K 319 K 210 K - 203 K 209 K 367 K - 435 K 397 K 379 K - 373 K 360 K 345 K - - - - - - - - - - - -10 K - - - - - - - - - - - -

EBITDA

- - - - - - - - - - -10.5 M - -21.4 M -21.4 M -19.6 M - -19.3 M -17.4 M -1.57 M - -11.4 M -11.8 M -12.5 M - -11.7 M -11.1 M -11.8 M - -6.28 M -7.66 M -7.23 M - -6.36 M -6.71 M -6.02 M -5.63 M -6.7 M -8.26 M -7.21 M -8.39 M -7.09 M -6.37 M -5.61 M - -4.24 M -3.71 M -2.15 M - -1.69 M -1.27 M -737 K - - - - - - - -

Operating Expenses

8.74 M 10.9 M 8.87 M - 11 M 9.97 M 10.9 M - 11.9 M 14.9 M 11.8 M - 23.4 M 23.1 M 20.4 M - 20 M 17.5 M 13.6 M - 11.5 M 11.8 M 12.5 M - 11.8 M 11.3 M 11.9 M - 6.37 M 7.72 M 7.3 M - 6.46 M 6.81 M 6.08 M - 6.77 M 8.33 M 7.28 M - 7.6 M 6.56 M 6 M - 4.6 M 4.08 M 2.53 M - 2.19 M 1.44 M 1.73 M - - - - - - - -

General and Administrative Expenses

3.29 M 3.78 M 3.73 M - 2.91 M 3.17 M 3.67 M - 5.01 M 7.47 M 4.84 M - 16.7 M 15.8 M 14.6 M - 15.4 M 12.8 M 6.7 M - 3.48 M 3.36 M 2.61 M - 2.48 M 2.78 M 2.24 M - 2.43 M 2.12 M 1.97 M - 2 M 2.36 M 2.06 M - 1.88 M 1.67 M 2.53 M - 4.14 M 3.28 M 2.21 M - 2.12 M 2.26 M 1.21 M - 1.14 M 918 K 1.09 M - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements SCYNEXIS SCYX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting SCYNEXIS plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.74 - $ 187 M canadaCanada
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
$ 0.76 - $ 54 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.27 - $ 1.72 B canadaCanada
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 5.4 - $ 86.3 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.92 - $ 402 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 4.82 - $ 635 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Emergent BioSolutions Emergent BioSolutions
EBS
$ 11.41 - $ 584 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.29 - $ 1.22 B usaUSA
Evoke Pharma Evoke Pharma
EVOK
$ 10.95 - $ 36.6 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 0.92 - $ 21.5 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
$ 21.36 - $ 2.03 B franceFrance
Solid Biosciences Solid Biosciences
SLDB
$ 5.87 - $ 240 M usaUSA
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 3.59 - $ 4.46 M usaUSA
Evolus Evolus
EOLS
$ 7.04 1.88 % $ 437 M usaUSA
Harrow Health Harrow Health
HROW
$ 47.06 - $ 1.53 B usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.55 -0.38 % $ 27.1 M chinaChina
Veru Veru
VERU
$ 2.42 - $ 326 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.92 - $ 2.53 B canadaCanada
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 2.53 1.61 % $ 35.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.06 - $ 122 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 13.14 - $ 1.81 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
$ 0.11 - $ 1.74 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 2.21 - $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
cbdMD cbdMD
YCBD
$ 1.2 - $ 5.18 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Tilray Tilray
TLRY
$ 12.15 - $ 7.51 B canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.75 - $ 18.3 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Viatris Viatris
VTRS
$ 11.65 - $ 14.1 B usaUSA